All About Cancer Biomarkers
Cancer biomarkers (CB) are biomolecules produced either by the tumor cells or by other cells of the body in response to the tumor. Most cancer biomarkers in clinical use are not suitable for population screening or for early diagnosis, and the use of prostate-specific antigen for prostate cancer screening is still controversial.
FDA approvals & product launches drive the market for cancer biomarkers. Market players are involved in the manufacturing wide range of cancer biomarkers that offer maximum advantages and early diagnosis. For instance, in May 2019, QIAGEN launched its first FDA-approved companion diagnostic for PIK3CA biomarkers to enhance precision medicine in breast cancer. PIK3CA Kit, the [PB1] first companion diagnostic assay are used in any cancer indication for the detection of activating mutations in the PIK3CA gene.
DOWNLOAD SAMPLE PDF COPY
Here are Some of the Key Companies Operating in Cancer Biomarkers Industry:
Bio-Rad Laboratories, Inc.
Thermo Fisher Scientific, Inc.
F. Hoffmann-La Roche Ltd.
QIAGEN N.V.
Illumina, Inc.
Myriad Genetics, Inc.
Hologic Inc.
Quest Diagnostics Incorporated
bioMĂ©rieux SA
Creative Diagnostics
Additionally, it is the first FDA approved test as guiding treatment decisions in breast cancer utilizing plasma specimens as a liquid biopsy. Moreover, In November 2017, Roche launched DISCOVERY [PB2] Teal HRP chromogen detection kit to improve tissue-based cancer research. This newest addition to the collection of modular-based detection kits is used to identify and profile biomarkers and cell populations in the tissue-based study.
Driving factors such as growing cancer prevalence across the globe, new product launches and FDA approvals, and technological advancements are expected to boost the market over the years. However, unfavorable regulatory and reimbursement scenario is likely to have a negative impact on the growth of the market in the coming years. In addition, the development opportunities in emerging countries are likely to have a positive effect on the growth of the market in the coming years.
The challenge and future prospective of biomarkers, by facilitating the combination of therapeutics with diagnostics, promise to play an important role in the development of personalized medicine.